

GLAXOSMITHKLINE LAVAL FACILITY BECOMES NORTH AMERICA VACCINE RESEARCH AND DEVELOPMENT HEADQUARTERS

\$50 million investment to support new role

Laval, Quebec, June 11, 2007 – GlaxoSmithKline (GSK) has designated its facility in Laval, Quebec, as the North American headquarters of its innovative vaccines division. The site will conduct leading vaccine research & development (R&D), and is also the administrative centre for the company's vaccines operations in North America. To support this crucial new role, GSK has created more than 60 new high calibre jobs and is completing an investment of \$50 million to expand and upgrade existing laboratory facilities, including the construction of a new state-of-the-art serology lab, clinical development and operational costs.

Scientists in Laval will focus research and development work in the areas of adjuvant technologies, molecular biology, immunology, respiratory viral vaccines, allergy, oncology and process development.

The announcement was made today in the presence of the Honourable Michael M. Fortier, Federal Minister of Public Works and Government Services and Minister Responsible for the Montreal Region; Mr. Raymond Bachand, Provincial Minister of Economic Development, Innovation and Export Trade and Minister of Tourism; Mr. Gilles Vaillancourt, Mayor of Laval and several other representatives from the business and academic communities.

"Today's announcement underlines GSK's intention to give Canada, and specifically Quebec, a pivotal role in its world-leading vaccine business," said Paul Lucas, President and CEO, GlaxoSmithKline Inc. (Canada). "GSK is proud to be contributing to the overall strength of the pharmaceutical and biopharmaceutical industry both in Quebec and in Canada as a whole, and we will continue to invest heavily in growing the company's pipeline to meet the demand for our innovative vaccines."

Mr. Lucas added that this development was only made possible through a supportive policy environment.

“There is significant global competition to attract investment in life sciences,” he said. “It is therefore gratifying to see the local, provincial and federal governments doing their part to ensure policies support innovation and patient health.”

Investments made in the Laval facility have already resulted in the creation of several high-calibre jobs in scientific research, and staffing will have increased by 20 per cent by the end of 2007.

This means that GSK is now the largest bio pharmaceutical employer in Quebec and in the country, with more than 1,400 employees in the province, and 3,300 in Canada.

“Our facilities and staff in Laval are playing a pivotal role in the development of new and innovative vaccines for the world while supporting a growing and vibrant R&D sector in Quebec and Canada,” said Nathalie Garçon, Head of Research and North America R&D, GlaxoSmithKline Biologicals.

GSK already supplies approximately 75 per cent of the Canadian government’s seasonal flu vaccine purchases. It is also working with federal and provincial governments to ensure appropriate pandemic preparedness.

With global headquarters in Rixensart, Belgium, GSK’s vaccines division is a world leader in the development and manufacturing of vaccines. In addition to the Laval facility, the vaccines division has four other facilities in North America which are located in Ste-Foy, Quebec; Hamilton, Montana; Columbia, Maryland; and Marietta, Pennsylvania.

About GlaxoSmithKline Biologicals

GlaxoSmithKline Biologicals (GSK Bio), one of the world’s leading vaccine manufacturers, is headquartered in Rixensart, Belgium, where the majority of GSK’s activities in the field of vaccine research, development and production are conducted. GSK Bio employs more than 1,500 scientists, who are devoted to discovering new vaccines and developing more cost-effective and convenient combination products to prevent infections that cause serious medical problems worldwide. GSK Bio is also developing innovative immunotherapy compounds to treat cancer patients.

About GlaxoSmithKline

GlaxoSmithKline – one of the world's leading research-based pharmaceutical and health-care companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer. In Canada, GlaxoSmithKline is among the top 15 investors in research and development, contributing more than \$176 million in 2006 alone. GSK is an Imagine Caring Company, and is consistently recognized as one of the 50 Best Employers in Canada. For company information, please visit www.gsk.ca.

-30-

For more information, please contact:

Marie-Christine Beauchemin
GlaxoSmithKline
(514) 956-3105

Peter Schram
GlaxoSmithKline
(905) 819-3363

Kenneth Inchausti
GlaxoSmithKline Biologicals
(267) 809-7552